BioCryst
Medical AFFAIRS
Navigate the Biocryst Medical Affairs Hub with ease
Throughout this resource hub you will find up-to-date information on developing and approved BioCryst medicines, including clinical trials, congress information, published data, and other research material.
Search for medical information
Find information on BioCryst products.
Find information
on upcoming and previous congresses
Upcoming Congress Events
Eastern Allergy Conference
BioCryst will attend the 2026 Eastern Allergy Conference from May 28 – May 31, 2026.
Visit the Congress Website for More Information
MSAAI
BioCryst will attend the 2026 MSAAI on June 06, 2026.
European Academy of Allergy and Clinical Immunology (EAACI) Congress
BioCryst will attend the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Congress from June 12 – June 15, 2026.
Materials From Recent Congresses
Showing 131 Materials
-
Long-Term, Sustained, Robust Hereditary Angioedema Attack Suppression with Navenibart Administered Every 3 and 6 Months: ALPHA-SOLAR Interim Results
AAAAI | 2026 | HAE -
Navenibart Demonstrates Durable Efficacy and Tolerability Across Biological Sexes: Subgroup Analysis from the ALPHA-STAR Trial
AAAAI | 2026 | HAE -
Navenibart Delays Time to First Attack in Hereditary Angioedema: Results from ALPHA-STAR
AAAAI | 2026 | HAE -
Real-World Attack Rate Reductions After Berotralstat Initiation Among Patients with Hereditary Angioedema with Normal C1-Inhibitor Stratified by Prior Long-Term Prophylaxis
AAAAI | 2026 | HAE -
Impact of Berotralstat on Hereditary Angioedema Attack Rates in Patients with C1-Inhibitor Deficiency: Real-World Evidence Stratified by Prior Long-Term Prophylaxis
AAAAI | 2026 | HAE
Current clinical trials and research
Learn more about medicines being developed at BioCryst and see the latest studies.
Discover more about our areas of focus
See our video library
Learn more about research within our areas of focus.
Ready to connect or have a question?
Have questions about any of our medicines that are approved or in development, or would you like to be connected with an MSL?
Have questions about our company?